Stock INKT MINK THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus MiNK Therapeutics, Inc.

Equities

INKT

US6036931029

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.9275 USD +6.46% Intraday chart for MiNK Therapeutics, Inc. +5.84% -13.32%
Mar. 21 Transcript : MiNK Therapeutics, Inc., Q4 2023 Earnings Call, Mar 21, 2024
Mar. 21 MiNK Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Evolution of the average Target Price on MiNK Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

3fbf426bebc5.i_BNUYqolm7UBAOuO07N5cvFhn8hPSNPd3ps75Lo8GI.0bYYF_nO2wLsbVPdfn6Uo4KQ1g5LRUwIBC0UifPQowv7uhsEyeDaI7lLbA~3038936811c9b27cb19062605974b578

Analyst Recommendations on MiNK Therapeutics, Inc.

HC Wainwright Adjusts MiNK Therapeutics Price Target to $10 From $7, Maintains Buy Rating MT
Evercore ISI Adjusts MiNK Therapeutics' Price Target to $3 From $4, Keeps Outperform Rating MT
HC Wainwright Initiates MiNK Therapeutics at Buy, Sets Price Target at $7 MT
B. Riley Lowers MiNK Therapeutics' Price Target to $7 from $10, Keeps Buy Rating MT
B. Riley Lowers MiNK Therapeutics' Price Target to $10 from $24 After Revising Cost Capital Assumptions, Keeps Buy Rating MT
B. Riley Starts MiNK Therapeutics at Buy with $24 PT, Notes 'Attractive' Valuation, Disruptive Potential of iNKT Platform MT
William Blair Initiates Coverage on MiNK Therapeutics With Outperform Rating MT
Evercore ISI Starts MiNK Therapeutics at Outperform With $30 Price Target MT
Baird Starts MiNK Therapeutics at Outperform With $26 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.9275 USD
Average target price
8 USD
Spread / Average Target
+762.53%
High Price Target
9 USD
Spread / Highest target
+870.35%
Low Price Target
7 USD
Spread / Lowest Target
+654.72%

Consensus detail

Consensus revision (last 18 months)

Analysts covering MiNK Therapeutics, Inc.

HC Wainwright
Evercore ISI
B. Riley
Baird
William Blair & Co.

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. INKT Stock
  4. Consensus MiNK Therapeutics, Inc.